glp-1 therapy protein intake optimization research ✨ peptides: beyond weight loss. At NOW Health, we specialize in precision peptide using Health Canada–approved GLP-1 and GIP receptor medications such as semaglutide and tirzepatide — advanced treatments that Frontiers | Investigating nutrient intake

GLP-1 medications are typically considered for adults who: Have a Body Mass Index (BMI) of 30 or higher Have a BMI of 27 or higher with weight-related conditions such as diabetes or hypertension Have not achieved sustained weight loss through lifestyle modification alone These medications are intended for long-term weight management, not short-term or cosmetic weight loss

Key characteristics: Structure: Five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) Classification: Third-generation GHRP Mechanism: Growth hormone secretagogue receptor (GHS-R) agonist Half-life: Approximately 2 hours Administration: Subcutaneous injection Ipamorelin was initially developed to accelerate gastrointestinal recovery after bowel surgery

As a full time worker, full time student, and full time mom, the convenience cannot be beat

Verdict at a Glance Pemvidutide and survodutide are both GLP-1/glucagon dual agonists being developed for obesity and MASH, but survodutide is further ahead in clinical development with more advanced Phase 3 programs, higher-tier regulatory designations (Breakthrough Therapy vs Fast Track), and greater weight loss in Phase 2 (18.7% vs 15.6%)